More than half of those responsible for registering clinical trials and reporting results fail to do so over confusion about key requirements, according to a new survey that highlighted ongoing difficulties in achieving transparency surrounding study data.
Specifically, 52% said their major challenges involved sorting out the types of clinical trials that must be registered, when a trial should be registered, and when and for which trials information from summary results must be submitted to a U.S. government database. Nearly 48% also pointed to principal trial investigators who fail to respond to the requirements.
Similar findings were disclosed for reporting trial results, with 56% saying there was confusion about which results must be submitted and 51% uncertain about regulatory timelines for providing this information. And 49% expressed uncertainty about when to report results information for unsuccessful trials, while 44% pointed to unresponsive principal investigators.